Management of Substance-Induced Hypertension

Initial Assessment and Stabilization

Assess for signs of acute intoxication, including euphoria, tachycardia, hypertension, agitation, and evaluate for end-organ damage (ECG changes, chest pain, neurological symptoms) in patients with suspected methamphetamine-induced hypertension, as recommended by the American Heart Association/American College of Cardiology 1
Initial stabilization should include administering benzodiazepines for agitation and autonomic hyperactivity, providing IV fluids for dehydration and to prevent rhabdomyolysis, and continuous cardiac monitoring in patients with methamphetamine-induced hypertension 1, 2

The American College of Cardiology recommends benzodiazepines combined with nitrates or calcium channel blockers as the first-line treatment for methamphetamine-induced hypertension, while beta-blockers should be avoided due to the risk of worsening coronary vasospasm 1, 3
For mild-moderate hypertension, benzodiazepines + sublingual nitroglycerin can be used, and for severe hypertension, IV calcium channel blocker (nicardipine or diltiazem) can be added and titrated to target blood pressure in patients with methamphetamine-induced hypertension 4
Calcium channel blockers, such as diltiazem (IV): 20 mg IV initially, are preferred agents for blood pressure control and can effectively reverse methamphetamine-induced coronary vasoconstriction 4

Avoid beta-blockers, including labetalol, in patients with signs of acute methamphetamine intoxication due to the risk of worsening coronary vasospasm and hypertension, with a Class III: Harm recommendation, as suggested by the American Heart Association/American College of Cardiology 1, 3
Nitrates, such as sublingual or IV nitroglycerin, are particularly useful for patients with chest pain or ECG changes and work synergistically with calcium channel blockers in patients with methamphetamine-induced hypertension 1, 4
Consider coronary angiography if symptoms persist in patients with chest pain or ECG changes, as recommended by the American College of Cardiology 4, 5

Encourage abstinence from methamphetamine, treat underlying cardiovascular conditions, and consider HMG-CoA reductase inhibitors (statins) for patients with atherosclerotic disease, as recommended by the American College of Cardiology 1
Monitor for development of chronic hypertension and cardiomyopathy, and recognize methamphetamine-associated pulmonary arterial hypertension (Meth-APAH) as a condition with worse outcomes compared to idiopathic PAH, as suggested by the American Heart Association/American College of Cardiology 1, 4
The treatment of methamphetamine intoxication should focus on benzodiazepines as first-line agents for agitation and autonomic hyperactivity, with additional supportive care based on specific clinical manifestations, as recommended by the European Society of Cardiology and the American Heart Association 2, 6, 1